{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:46:49Z","timestamp":1783486009527,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jgar.2019.10.009","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:48:35Z","timestamp":1571662115000},"page":"60-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Antimicrobial activity of ceftolozane\/tazobactam tested against contemporary (2015\u20132017) Pseudomonas aeruginosa isolates from a global surveillance programme"],"prefix":"10.1016","volume":"21","author":[{"given":"Dee","family":"Shortridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2019.10.009_bib0005","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care\u2014associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2019.10.009_bib0010","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Pseudomonas aeruginosaEpidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible collected during 2009\u201311 in 14 European and Mediterranean countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.jgar.2019.10.009_bib0015","first-page":"8","article-title":"Epidemiology of antibiotic resistance in Pseudomonas aeruginosa. Implications for empiric and definitive therapy","volume":"30","author":"Ruiz-Garbajosa","year":"2017","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jgar.2019.10.009_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14787210.2018.1425139","article-title":"Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward \u201cmolecularly targeted\u201d therapy","volume":"16","author":"El Chakhtoura","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2019.10.009_bib0025","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1093\/jac\/dku184","article-title":"Pseudomonas aeruginosaAntimicrobial activity of ceftolozane\/tazobactam tested against and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011\u201312)","volume":"69","author":"Sader","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2019.10.009_bib0030","series-title":"ZERBAXA\u00ae (ceftolozane\/tazobactam)","author":"Merck & Co. Inc","year":"2019"},{"key":"10.1016\/j.jgar.2019.10.009_bib0035","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.diagmicrobio.2013.03.032","article-title":"Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007\u20132009 SENTRY antimicrobial surveillance program","volume":"76","author":"Kaiser","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.009_bib0040","series-title":"Performance standards for antimicrobial susceptibility testing: 29th informational supplement, M100","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2019"},{"key":"10.1016\/j.jgar.2019.10.009_bib0045","series-title":"Breakpoint tables for interpretation of MICs and zone diameters","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)","year":"2019"},{"key":"10.1016\/j.jgar.2019.10.009_bib0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2019.10.009_bib0055","doi-asserted-by":"crossref","first-page":"e00465","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane\u2013tazobactam activity against Pseudomonas aeruginosa clinical isolates from U.S. hospitals: report the PACTS antimicrobial surveillance program, 2012 to 2015","volume":"61","author":"Shortridge","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.009_bib0060","doi-asserted-by":"crossref","first-page":"e01589","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain","volume":"61","author":"Del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2019.10.009_bib0065","doi-asserted-by":"crossref","first-page":"25543","DOI":"10.1038\/srep25543","article-title":"Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2019.10.009_bib0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bjid.2016.09.011","article-title":"Emergence of colistin resistance in the largest university hospital complex of Sao Paulo, Brazil, over five years","volume":"21","author":"Rossi","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.009_bib0075","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Pseudomonas aeruginosaCeftolozane\u2013tazobactam for the treatment of multidrug-resistant infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2019.10.009_bib0080","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, MO7","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716519302632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:54:59Z","timestamp":1761990899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716519302632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":16,"alternative-id":["S2213716519302632"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2019.10.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of ceftolozane\/tazobactam tested against contemporary (2015\u20132017) Pseudomonas aeruginosa isolates from a global surveillance programme","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2019.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}